Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: bevacizumab, vinorelbine tartrate, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rett Syndrome, Prader-Willi Syndrome, Angelman Syndrome, Sleep Problems
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 18 Years
Enrollment: 804 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Birmingham, Alabama • Irvine, California • San Diego, California + 6 more

Conditions: Lymphoma
Interventions: rituximab, yttrium Y 90 ibritumomab tiuxetan; Biological · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Lung Cancer, Non-small Cell Lung Cancer
Interventions: PET/CT and BH PET/CT; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Cervical Stenosis, Myelopathy, Cervical Spondylosis With Myelopathy, Degenerative Disc Disease, Radiculopathy
Interventions: Primary Anterior Cervical Discectomy Procedures; Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Docetaxel, Prednisone, LDE225; Drug
Lead sponsor: Martin Gutierrez; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Chronic Atrial Fibrillation, Persistent Atrial Fibrillation
Interventions: RF ablation PVI alone, RF ablation PVI plus LPAW; Procedure
Lead sponsor: Sequoia Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Posterior Vitreous Detachment, Myopic Vitreopathy, VISION DEGRADING MYODESOPSIA
Interventions: Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser therapy; Device
Lead sponsor: VMR Consulting, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Huntington Beach, California

Conditions: Androgenetic Alopecia
Interventions: Topical SM04554 solution, Topical vehicle solution; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Encinitas, California • San Diego, California • New Haven, Connecticut + 20 more

Conditions: Malaria
Interventions: VRC-MALMAB0114-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: Rest, Aerobic Activity; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Community-acquired Pneumonia
Interventions: Doxycycline, Azithromycin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more

Conditions: Obsessive Compulsive Disorder (OCD)
Interventions: CBT for pediatric OCD; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 8 Years to 16 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Multiple Myeloma, Plasma Malignancy
Interventions: genetic sequencing; Genetic
Lead sponsor: Multiple Myeloma Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 19
States / cities: Scottsdale, Arizona • Duarte, California • San Francisco, California + 15 more

Conditions: Covid-19 (SARS-CoV-2)
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
Interventions: DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab, Ipilimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 12 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo; Drug · Behavioral
Lead sponsor: Michael Aman; Other
Eligibility: 6 Years to 12 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more

Conditions: Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Interventions: EYE201; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 26
States / cities: Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more

Conditions: Recurrent Prostate Cancer, Stage IV Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: tanespimycin, docetaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Acquired Immunodeficiency Syndrome, HIV Infection
Interventions: Genetically Marked Syngeneic T Lymphocytes; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Interventions: TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent; Drug
Lead sponsor: TORL Biotherapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Fullerton, California • Los Alamitos, California • Santa Monica, California + 6 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Lenalidomide; Drug
Lead sponsor: Thomas Kipps; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Interventions: cytotoxic t-lymphocytes; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Month to 79 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 544 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Durham, North Carolina

Search by objective public record fields.

Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW

Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis

Assessing Microbiome in Primary Anterior Cervical Fusion Patients

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

Comparison of Two Pulmonary Vein Ablation Techniques for Persistent AF

YAG Laser Vitreolysis for Vitreous Floaters

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

Trial to Evaluate L9LS in Healthy Adults

Exercise-priming of CBT for Depression: the CBT+ Trial

Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams

Neuropsychological Profiles of Pediatric Obsessive Compulsive Disorder (OCD)

MMRF Molecular Profiling Protocol

Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Treatment of Severe Childhood Aggression (The TOSCA Study)

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

Safety and Survival of Genetically Modified White Blood Cells in HIV-Infected Persons - A Study in Identical Twin Pairs

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine